What Institut Godinot does

Institut Godinot is a non-profit comprehensive cancer center (Centre de Lutte Contre le Cancer / CLCC) located in Reims, France, founded in 1924 and operating as an établissement d'utilité publique under Article L6162-2 of the French Public Health Code. It is a member of the Unicancer network, which groups 18 CLCCs across France and constitutes the only non-profit hospital network dedicated to oncology in Europe. The institute provides the full continuum of cancer care — screening, diagnosis, treatment (surgery, chemotherapy, radiotherapy, immunotherapy, hormonotherapy, targeted therapy), supportive care, rehabilitation, and palliative care — across nine medical departments: medical imaging, medical oncology, radiotherapy, surgical oncology, nuclear medicine, anatomocytopathology, support care, anesthesia-resuscitation, and pharmacy.

The technical platform is anchored by six particle accelerators (Halcyon, Radixact, Versa HD, Infinity, plus two additional units and an EDGE system being installed in 2026), two TEP/PET scanners (the second installed March 2024), robotic surgery systems, 3D and tomosynthesis mammography, AI-assisted intraoperative ultrasound, ICG fluorescence imaging, tomotherapy, brachytherapy (HDR, PDR, and permanent iodine-125 implants), and Radiothérapie Interne Vectorisée (RIV) for thyroid, neuroendocrine, and metastatic prostate cancers. A Biological Resources Centre holds dual ISO 9001:2015 and ISO 20387:2018 certifications, and the Clinical Research Bureau is ISO 9001:2015 certified. Clinical research activity runs over 600 active trials via the Unicancer network, including a newly created Early Phase Unit (UPP) for Phase I trials.

The institute serves approximately 25,582 active patients per year across 83,277 medical acts and consultations, with operations spanning five sites in Reims (main hospital, city-center consultations, SMR partnership with CHU de Reims), Soissons (satellite radiotherapy since 2019), and Charleville-Mézières (satellite radiotherapy since June 2025, with an oncopole planned for 2028). It employs 600+ dedicated personnel and trains 100+ students and residents daily through partnerships with Université de Reims Champagne Ardenne and CHU de Reims. Revenue derives from French public healthcare reimbursement (Sécurité sociale, no excess charges), donations/legacies (tax-incentivized), and academic/industry research funding. Governance is provided by a Board chaired by the Préfet de la Marne; executive leadership is held by Professor Yacine Merrouche (Director General) and Laurence Cariven (Deputy Director General).

Name

Institut Godinot

Legal name

Institut Godinot

Website

https://centenaire-institutgodinot.fr

Company type

Private

Founded year

1924

Operating status

Operating

Headcount range

251–500 employees

Short description

Institut Godinot is a French non-profit comprehensive cancer center (CLCC) in Reims, part of the Unicancer network, delivering multidisciplinary oncology care — radiotherapy, chemotherapy, surgery, nuclear medicine, imaging, and clinical research — to cancer patients across the Grand Est region.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Urologic Oncology (HLAKAOAB)

Keywords

• Oncology services
• Cancer treatment
• Radiation therapy
• Clinical research
• Medical imaging

Headquarters

HQ city

Reims, Grandest

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Public Healthcare Reimbursement: As a public health establishment (Établissement de santé) under Article L6162-2 of the French Public Health Code, the institute is funded through the French national health insurance system (Sécurité sociale). Patient care is reimbursed through standard public healthcare mechanisms with no additional charges (sans dépassement d'honoraires).
2. Donations and Legacies: Authorized to receive donations, bequests, and life insurance contributions. Donations from individuals (66% income tax reduction) and companies (60% corporate tax reduction) support equipment, research, and patient well-being initiatives.
3. Research Funding: Part of the Unicancer network which conducts over 600 active clinical trials. Research is funded through academic partnerships, pharmaceutical collaborations, and public research grants.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

Institut Godinot is a comprehensive non-profit cancer center (CLCC) delivering integrated oncology care — diagnosis, surgery, chemotherapy, targeted therapy, immunotherapy, external radiotherapy, brachytherapy, internal vectorized radiotherapy (RIV), nuclear medicine, supportive care, palliative care, oncological rehabilitation, and clinical research — across all cancer types (breast, gynecological, thoracic, urological, ORL, digestive, dermatological, thyroid). It operates nine medical departments on a five-site territorial network anchored in Reims with satellite radiotherapy at Soissons and Charleville-Mézières, and conducts research through the Unicancer network covering 600+ active clinical trials.

Product overview

Institut Godinot is a comprehensive cancer center (CLCC) organized as a platform of nine medical departments providing integrated oncology services: medical imaging, medical oncology, radiotherapy, surgical oncology, nuclear medicine, anatomopathology, support care, and pharmacy. The center operates across five sites in the Champagne-Ardenne region (Reims main site, Reims city center consultations, Soissons and Charleville-Mézières radiotherapy satellites, and CHU de Reims rehabilitation). Key treatment platforms include diagnostic imaging (MRI, PET-CT, mammography, gamma cameras) and therapeutic equipment (six particle accelerators, brachytherapy systems, radiopharmaceutical facilities). Specialized services include Internal Vectorized Radiotherapy (RIV), Medical Rehabilitation (SMR), patient experience spaces, and clinical research with over 600 active trials via the Unicancer network.

Differentiator

Problem solved

Functional benefit

Products and services

• Département d'Oncologie Médicale (Medical Oncology) Comprehensive medical oncology service delivering personalized cancer treatment including chemotherapy, targeted therapies, immunotherapy, and hormonotherapy for all cancer types. Serves cancer patients referred by GPs and specialists across the Champagne-Ardenne region.
• Département de Radiothérapie (Radiotherapy) Radiotherapy department offering external beam radiotherapy with image-guided IMRT/VMAT across six particle accelerators (HALCYON, RADIXACT, VERSA HD, INFINITY plus an EDGE), brachytherapy/curietherapy (HDR, PDR, permanent Iodine-125), and tomotherapy. Serves cancer patients across Reims, Soissons, and Charleville-Mézières.
• Radiothérapie Interne Vectorisée (RIV) Innovative targeted internal radiotherapy that delivers radioactive substances via vectors that specifically bind to tumor cells, sparing healthy tissue. Used for thyroid cancers, neuroendocrine tumors, and metastatic prostate cancer.
• Département de Chirurgie Carcinologique (Oncological Surgery) Oncological surgery department providing surgical interventions for breast, gynecological, head and neck, dermatological, digestive, and thyroid cancers using robotic-assisted surgery, intraoperative ICG fluorescence, AI-assisted ultrasound, and 3D surgical planning/reconstruction.
• Département de Médecine Nucléaire (Nuclear Medicine) Nuclear medicine department providing diagnostic imaging (PET scans, scintigraphy with two TEP units) and therapeutic radiopharmaceutical treatments.
• Département d'Imagerie Médicale (Medical Imaging) Medical imaging department offering MRI, CT scanner, 3D tomosynthesis mammography with stereotactic biopsy, and high-resolution ultrasound, staffed by radiologists specialized in oncology.
• Département d'Anatomocytopathologie (Pathology) Anatomocytopathology department providing tissue and cell analysis for precise tumor diagnosis and biological characterization, supported by an ISO 9001:2015 and ISO 20387:2018 certified Centre de Ressources Biologiques.
• Département des Soins de Support (Supportive Care) Interdisciplinary supportive care department providing pain management, nutrition, psychological support, physiotherapy, socio-aesthetics, sexual health, photobiomodulation, and palliative care.
• Département de Pharmacie (Hospital Pharmacy) Hospital pharmacy department managing medication procurement, sterile preparation of chemotherapies, and radiopharmaceutical preparations (29,061 chemotherapy preparations in 2025).
• Soins Médicaux et de Réadaptation (SMR) Oncologie Oncological medical and rehabilitation care unit unique in the Champagne-Ardenne territory, operated in partnership with CHU de Reims, providing functional recovery, autonomy improvement, and quality of life enhancement for cancer patients.
• Recherche Clinique (Clinical Research)

Quantifiable outcome

• 99% HAS certification score demonstrating excellence in care delivery
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability1 record

Feature10 records

Partnerships

Seven partnerships are on record, tiered major, minor and core.

• Centre Hospitalier Intercommunal Nord-ArdennesmajorStrategic or Co-development Partner · 1 January 2028Future partnership planned for 2028 oncopole project in Charleville-Mézières, prefigured by the current radiotherapy service at Clinique du Parc.
• RESPADDminorStrategic or Co-development Partner · 1 January 2025Partnership for 'Lieu de Santé Sans Tabac' (LSST) initiative. Signed the RESPADD LSST Charter with Bronze certification obtained October 8, 2025. Committed to tobacco-free health environment, smoking cessation support, and health promotion.
• Unicancer NetworkcoreStrategic or Co-development PartnerInstitut Godinot is a member of the Unicancer network, which groups 18 Centres de Lutte Contre le Cancer (CLCC) in France and two affiliated establishments. This exclusively non-profit hospital network dedicated to oncology constitutes a unique model in Europe. The network shares the mission of guaranteeing excellent, human, innovative, and accessible care for all patients across the entire territory. Unicancer is recognized as the leading European academic promoter in clinical oncology research, conducting over 600 active clinical trials.
• Université de Reims Champagne Ardenne (URCA)coreStrategic or Co-development PartnerEducational partnership with URCA for coordinated training programs including DES, FST, DIU, IPA diplomas, and 2nd cycle teaching units. Students benefit from access to all institute activities covering care, teaching, and research.
• CHU de ReimscoreStrategic or Co-development PartnerPartnership for Soins Médicaux et de Réadaptation (SMR) Oncologie service, unique in Champagne-Ardenne. Also collaborates on paramedical training establishments and research activities.
• Maison Hôtelière des familles et des patientsminorOthersPartnership accommodation facility near CHU de Reims and Institut Godinot, offering comfortable and warm environment for patients and families with demi-pension formula at moderate prices and 24/7 access.
• CH de SoissonsminorStrategic or Co-development PartnerHost site for satellite radiotherapy service of Institut Godinot since 2019, allowing patients in Aisne territory to receive radiotherapy without traveling to Reims.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Centre Paul Strauss: Strasbourg-based Unicancer CLCC serving the Alsace region. Comparable in regional-territorial catchment in eastern France, providing medical oncology, radiotherapy and surgery.
• Institut Bergonié: Bordeaux-based Unicancer CLCC providing comprehensive cancer care, surgery, radiotherapy and medical oncology. Direct comparable as a French regional specialty oncology hospital inside the same network.
• Gustave Roussy: Largest French CLCC and leading European cancer center, located just outside Paris. Operates the same non-profit CLCC model under Unicancer with comparable comprehensive oncology departments, clinical research and inpatient specialty cancer care.
• Centre François Baclesse: Caen-based Unicancer CLCC serving Normandy. Comparable comprehensive cancer center operating clinical research, radiotherapy (including high-precision platforms) and surgical oncology.
• Institut Curie: Paris-based CLCC and research center combining hospital care, research and teaching in oncology. Directly comparable model as a French comprehensive cancer center with a strong research portfolio and specialized radiotherapy/surgery platforms.
• Centre Léon Bérard: Lyon-based CLCC within Unicancer offering comprehensive cancer care, clinical research and satellite radiotherapy. Closely comparable in scope and operating model to Institut Godinot at a similarly sized regional-territorial scale.
• Institut de Cancérologie de l'Ouest (ICO): Western France CLCC within Unicancer with two sites (Angers, Saint-Herblain). Comparable multi-site French specialty oncology hospital with research, radiotherapy satellites and surgical oncology.
• Institut du Cancer de Montpellier (ICM): Montpellier-based Unicancer CLCC covering medical oncology, radiotherapy, surgery and research. Directly comparable as a French CLCC of similar size and care scope.

Regional players

• Institut de Cancérologie Strasbourg Europe (ICANS): Newly consolidated Strasbourg/Alsace comprehensive cancer center created as a partnership between CLCC and CHU. Geographically nearest direct competitor to Institut Godinot in the Grand Est oncology market.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: Global reference specialty oncology hospital combining patient care, research and teaching. Useful comparable for the academic/research positioning, scale of clinical trials and specialty cancer hospital model Institut Godinot operates at a more regional footprint.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/institut-godinot-reims

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Godinot